Piramal Pharma Limited — Updates, 23-10-2024: Press Release

Piramal Pharma Limited reported strong financial results for Q2 and H1 FY25, with a 17% year-over-year revenue increase to ₹2,242 crore. The EBITDA grew by 28%, reaching ₹403 crore, while PAT surged by 350% to ₹23 crore. Key growth drivers included the Contract Development and Manufacturing Organization (CDMO) segment and productivity initiatives. The company also announced an $80 million expansion at its Lexington facility and released its FY2024 Sustainability Report, emphasizing its long-term sustainability goals.